Sartorius/€SRT3

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sartorius

Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.

Ticker

€SRT3
Sector

Primary listing

XETRA

Employees

13,685

Sartorius Metrics

BasicAdvanced
€12B
-
-
1.24
€0.74
0.38%

What the Analysts think about Sartorius

Analyst ratings (Buy, Hold, Sell) for Sartorius stock.

Bulls say / Bears say

In H1 2025, the Bioprocess Solutions division achieved 8.8% constant-currency sales growth to €1.435 billion and increased its underlying EBITDA margin to 31.6%, driven by strong demand for high-margin consumables (European Financial Times)
The Group's underlying EBITDA climbed 11.9% to €527 million in H1 2025, raising the margin by 1.7 percentage points to 29.8%, demonstrating efficient operations despite ongoing market headwinds (Reuters)
Net debt to underlying EBITDA improved to 3.8x as of June 30, 2025 from 4.0x at 2024 year-end, enhancing Sartorius’s financial flexibility and supporting its investment grade standing (European Financial Times)
The Lab Products & Services segment saw a 4.8% constant-currency sales decline to €332 million in H1 2025, with underlying EBITDA margin dropping to 22.3%, indicating ongoing weakness in lab equipment demand (European Financial Times)
Analysts noted that the trailing 12-month book-to-bill ratio for the Bioprocess Solutions division fell below 1 in Q2, leading to a 4.6% share price decline as concerns over order momentum increased (Reuters)
JP Morgan’s cautious view, with Q1 2025 underlying EBITDA estimates 3% below the consensus and lower full-year sales forecasts, triggered a roughly 4% drop in the stock, highlighting the share’s sensitivity to broker downgrades (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.

Sartorius Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sartorius Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SRT3

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs